Breeze Holdings Acquisition Corp. shareholders approve the business combination with YD Biopharma Limited.
The combined company will be named YD Bio Limited and is expected to trade on Nasdaq under the ticker symbol 'YDES' in the coming days.
The special meeting of stockholders on August 14, 2025, resulted in overwhelming approval of the Business Combination Proposal.
Stockholder Approval
Overwhelming approval from Breeze Holdings Acquisition Corp. stockholders for the business combination with YD Biopharma Limited.
New Ticker Symbol
The combined company will trade on Nasdaq under the new ticker symbol 'YDES'.
Expected Closing
The closing of the transaction is expected within the next two weeks, subject to customary closing conditions.
- YD Biopharma Limited's focus on cancer prevention medical diagnostics and innovative therapeutics positions the combined company for future growth in high-demand markets.
- The approval of the business combination strengthens the strategic position of YD Biopharma Limited in the biopharmaceutical industry.
The approval of the business combination signifies a significant milestone for both Breeze Holdings Acquisition Corp. and YD Biopharma Limited, paving the way for enhanced opportunities and growth in the biopharmaceutical sector.